

# OIE Reference Laboratory Reports Activities

## *Activities in 2020*

**This report has been submitted : 2021-02-11 11:17:10**

<b>Name of disease (or topic) for which you are a designated OIE Reference Laboratory:</b>	Contagious equine metritis
<b>Address of laboratory:</b>	APHA Penrith Merrythought, Calthwaite, Penrith, CA119RR UNITED KINGDOM
<b>Tel.:</b>	+44-3000 600012
<b>Fax:</b>	
<b>E-mail address:</b>	ian.mawhinney@apha.gov.uk
<b>Website:</b>	
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Dr K Line
<b>Name (including Title and Position) of OIE Reference Expert:</b>	Ian Mawhinney
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental

**ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards**

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
none	na	na	na
Direct diagnostic tests			
Culture	Yes	2017	
RT-PCR	Yes	216	

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.  
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

**ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases**

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

**ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries**

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
SOUTH AFRICA	PCR process	Telephone

**ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations**

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
PCR validation	since 2108 and ongoing	PCR validation by use in different laboratories than the intila	USDA, WUR AFSA Canada	UNITED STATES OF AMERICA

**ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases**

11. Did your Laboratory collect epizootiological data relevant to international disease control?

No

If the answer is no, please provide a brief explanation of the situation:
Not in our remit

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
analysis of 10 years of ring trial data

**13. What method of dissemination of information is most often used by your laboratory?  
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 2  
10 years of ring trials - OIE Technical Report  
Pathogenicity of *T. asinigenitalis* - Eq Vet J

b) International conferences: 0

c) National conferences: 0

d) Other:  
(Provide website address or link to appropriate information) 0

**ToR 7: To provide scientific and technical training for personnel from OIE Member Countries  
To recommend the prescribed and alternative tests or vaccines as OIE Standards**

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

**ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned**

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO17025:2017	Certificate of accreditation 17025 2017.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Taylorella equigenitalis (CEMO) culture for International Trade	UKAS
Taylorella equigenitalis & T. asinigenitalis PCR	UKAS

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

No

*(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)*

**ToR 9: To organise and participate in scientific meetings on behalf of the OIE**

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

**ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results**

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: <sup>1</sup>	Role of your Reference Laboratory (organiser/participant)	No. participants	Participating OIE Ref. Labs/organising OIE Ref. Lab.
Ring Trial	organiser	20+	USA, Netherlands/UK

<sup>1</sup> validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
PCR validation	Reproducibility study	UK, USDA, Netherlands

**ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results**

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons <sup>1</sup>	No. participating laboratories	Region(s) of participating OIE Member Countries
Ring trial for culture and PCR	20+	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input checked="" type="checkbox"/> Middle East

**ToR 12: To place expert consultants at the disposal of the OIE**

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
Expert input	email	Terrestrial Code and Diagnostic Manual

25. Additional comments regarding your report: